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Abstract: The development of imatinib has revolutionized the treatment of chronic myeloid 
leukemia. Follow-up analysis of IRIS trial participants continues to demonstrate durable 
responses for imatinib at 400 mg/day. However, 10%–15% of patients with chronic myeloid 
leukemia will become imatinib-resistant or intolerant of adverse events. Phase II studies have 
shown that most of these patients will respond to second-generation tyrosine kinase inhibitors, 
such as nilotinib, dasatinib, and bosutinib. Both nilotinib and dasatinib have recently demon-
strated clinical efficacy as frontline therapy in Phase III studies. In the ENESTnd trial, nilotinib 
600–800 mg/day produced significantly higher major molecular rates and complete cytogenetic 
response rates in comparison with imatinib at 12 months. Recently, 18-month follow-up analysis 
of this trial continues to demonstrate superiority for nilotinib. It is unknown whether this 
will ultimately translate into improved long-term outcomes, such as event-free survival or 
overall survival. Nilotinib continues to be generally well tolerated and tends to produce less 
Grade 3/4 toxicity in frontline therapy when compared with its use following imatinib failure. 
With three tyrosine kinase inhibitors for potential frontline therapy and an active drug discovery 
pipeline, treatment for chronic myeloid leukemia is still subject to change with time as clinical 
algorithms continue to evolve.
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Introduction
Chronic myeloid leukemia (CML) is a chronic myeloproliferative disorder that 
  represents approximately 15% of all adult leukemias, with an estimated 4870 new cases 
in the US in 2010.1 The treatment of this disease has dramatically improved with the 
advent of targeted oral tyrosine kinase inhibitors (TKIs). Prior to the Phase III IRIS 
(International Randomized Interferon-α and STI-571) study, the standard of care was 
cytarabine and interferon-α in those patients who were unable to undergo   allogeneic 
hematopoietic stem cell transplantation. Imatinib (STI-571, Gleevec®; Novartis, Basel, 
Switzerland) demonstrated superiority in response rates and overall survival when 
compared with cytarabine and inferferon-α.2 Several follow-up analyses of IRIS study 
participants have continued to confirm the efficacy and safety of imatinib.3–5 However, 
some patients will develop imatinib resistance or intolerance to therapy. Imatinib 
intolerance is a significant clinical issue which leads to dose reduction or   discontinuation. 
Adverse events associated with imatinib intolerance include myelosuppression, 
  arthalgia/myalgia, fatigue, rash, and gastrointestinal symptoms. A 4-year analysis 
from the HealthCore Managed Care database revealed that, among 156 patients Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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receiving imatinib 400 mg/day, 21% required a dose 
  reduction to 100 mg/day. The most common reasons for 
dose reduction were neutropenia, anemia, and nausea/
vomiting.6 In patients who develop resistance, higher doses 
of imatinib (600–800 mg/day) have been attempted.7 These 
patients are particularly subject to imatinib intolerance. 
Patients who received imatinib 600 mg/day and 800 mg/day 
required dose reductions of 59% and 67%, respectively, most 
commonly for myelosuppression. The development of 
second-  generation TKIs (dasatinib, nilotinib, bosutinib) has 
provided new options for CML patients, specifically those 
patients who are intolerant of or resistant to imatinib.
Dasatinib (BMS-354825, Sprycel®; Bristol-Myers Squibb, 
New York, NY) received accelerated approval in June 2006 
for the treatment of patients with chronic phase, accelerated 
phase, or blast crisis CML who were imatinib-resistant and/or 
imatinib-intolerant. In October 2007, nilotinib (AMN107, 
Tasigna®; Novartis) was also granted accelerated approval 
for patients with chronic phase or accelerated phase CML 
deemed imatinib-resistant and/or imatinib-intolerant. 
  Bosutinib (SKI-606) has not received US Food and Drug 
Administration (FDA) approval to date.
All three second-generation TKIs have demonstrated 
clinical benefit in multiple Phase II studies8–14 in patients with 
resistance and/or intolerance to imatinib. In June 2010, 
data were published for dasatinib and nilotinib in the front-
line therapy setting for patients with chronic phase CML. 
Since this time, the FDA has granted approval for both 
dasatinib and nilotinib in newly diagnosed patients. The aim 
of this review is to examine the role of nilotinib in frontline 
therapy for CML. Specifically, this paper compares TKI 
response rates in frontline therapy, evaluates the adverse 
event profiles associated with these agents, and discusses 
specific TKIs according to their BCR–ABL mutation status.
Pharmacology
CML results from reciprocal translocation between chromo-
somes 9 and 22, which results in the Philadelphia chromosome. 
This event adds a 3′ segment of the Abelson (ABL) gene from 
chromosome 9q34 to the 5′ part of the BCR gene on chromo-
some 22q11, creating a hybrid BCR–ABL gene.15 The BCR–
ABL transcript is also found in approximately 25% of 
patients with B cell acute lymphoblastic leukemia.16 The dis-
ruption of the ABL protein results in a constitutively active 
tyrosine kinase which promotes proliferation, resistance to 
apoptosis, and alters cell adhesion. The development of 
small molecule TKIs that would occupy the adenosine 
triphosphate-binding site in the ABL kinase domain was 
pursued. By creating compounds that would reside in the 
adenosine triphosphate-binding pocket, this would prevent 
the phosphorylation of numerous substrates and trap the ABL 
kinase in the inactive conformation. This was first achieved 
by the development of the phenylaminopyrimidine deriva-
tives that were synthesized and screened. One of the com-
pounds (CGP 57148) had activity against platelet-derived 
growth factor, c-KIT, and BCR–ABL; later this compound 
became known as STI571, or imatinib.17,18 Although this 
discovery has dramatically improved the treatment of CML, 
the emergence of imatinib resistance has presented therapeu-
tic challenges.
Like imatinib, nilotinib binds to the inactive conformation 
of the ABL tyrosine kinase.19 However, crystallographic 
studies have revealed an improved topological fit for the 
ABL protein.20 This is due to the design of more potent 
compounds that incorporate alternative binding groups. 
Altering the structure of imatinib, which participates in 
hydrogen bonding at Ile360 and His361, nilotinib is designed 
to have more affinity for the kinase domain of ABL protein.21 
Nilotinib is at least 30 times more potent than imatinib in 
cell lines expressing BCR–ABL. IC50 values which inhibit 
the autophosphorylation of various kinases are as follows: 
BCR–ABL (20–60 nM), platelet-derived growth factor 
(71 nM), and c-KIT (200 nM).20 Unlike other second- 
generation TKIs (dasatinib and bosutinib), nilotinib has 
minimal effects on Src family kinases (IC50 values: c-Src, 
4600 ± 520 nM; Lyn, 2700 ± 460 nM; Hck, 7500 ± 830 nM).21,22 
Src family kinases are a family of nine nonreceptor tyrosine 
kinases that play a role in cellular adhesion, angiogenesis, 
growth, and survival. Inhibition of Src family kinases is an 
attractive target in anticancer therapeutics, particularly 
in CML, because Src family kinases are able to activate 
BCR–ABL, and Hck and Lyn can become BCR–ABL- 
independent.23 Overexpression or activation of Hck and Lyn 
can occur in CML progression.24 Increased expression of 
Lyn kinase has been associated with nilotinib resistance 
in vitro.25 This lack of Src family kinase inhibition by nilo-
tinib suggests that dasatinib should be favored as an initial 
CML treatment option. However, because Lyn is an impor-
tant modulator of erythropoiesis and Hck is involved in the 
survival of myeloid cells and B lymphocytes, it has been 
proposed that nilotinib may have a more favorable adverse 
event profile with regard to myelosuppression.26–28 In fact, 
this has been demonstrated in clinical trial data where patients 
with chronic phase or accelerated phase CML who have Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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received dasatinib have increased rates of Grade 3/4 adverse 
hematologic events.29,30
Monitoring therapy
The goals of current CML treatment are to reduce or eradicate 
the Philadelphia chromosome and BCR-ABL gene expres-
sion, to minimize adverse events for patients, and to improve 
event-free survival, progression-free survival, and overall 
survival. Oral TKI-based therapies are assessed for their 
ability to induce a complete hematologic response, complete 
cytogenetic   remission, and major molecular remission31 (see 
Table 1 for definitions). A complete hematologic response is 
a normalization of peripheral blood counts with the absence 
of blasts and promyelocytes in peripheral blood.31 It is recom-
mended that patients achieve a complete hematologic 
response within 3 months of initiating an oral TKI.31 Cyto-
genetics is the most commonly used technique to assess 
response to therapy. Conventional metaphase cytogenetic 
testing analyzes   Philadelphia chromosome-positive bone 
marrow cells in a sample of $20 cells.32 Definitions for 
cytogenetic response are as follows: none, with .95% Phila-
delphia metaphases;   minimal, 66%–95% Philadelphia meta-
phases; minor, 36%–65% Philadelphia metaphases; partial, 
1%–35%   Philadelphia metaphases; and complete cytogenetic 
remission, no Philadelphia metaphases. If conventional cyto-
genetics is performed and no analyzable metaphases are 
identified,   fluorescent in situ hybridization can be utilized 
with peripheral blood samples or bone marrow aspirates.33 
Fluorescent in situ hybridization assesses cytogenetic 
response in interphase cells and has a false positive rate of 
1%–10%.1,32,34   Hypermetaphase fluorescent in situ hybridiza-
tion provides greater sensitivity and can analyze 500 meta-
phases within an hour.35 Clinicians should use fluorescent in 
situ hybridization results with prudence; achievement of a 
complete cytogenetic remission cannot be confirmed by this 
method once Philadelphia levels are ,5%–10%.1,32
The most sensitive assay for assessing molecular response 
is the quantitative reverse-transcriptase polymerase chain 
reaction. This assay measures BCR–ABL transcripts, and can 
be used for both peripheral blood and bone marrow samples. 
Results are expressed as log reductions; this is derived from 
30 patients with untreated chronic phase CML who received 
imatinib in the original IRIS trial.36 In these patients, a .3-log 
reduction of BCR–ABL transcripts were noted and resulted 
in a lack of disease progression. A major molecular remission 
is defined as a $3-log reduction in BCR–ABL transcripts or 
BCR–ABL/ABL ratio reduced to #0.1% on an international 
scale.31,36 Because the original 30 patient samples are no longer 
available for commercial standardization, collaboration 
between institutions has been essential in establishing a stan-
dard quantification of this process.37 The creation of interna-
tional standardization led to a conversion factor which has 
allowed multiple academic institutions and private laboratories 
to improve their accuracy and reproducibility of BCR–ABL 
testing.37–39 A quantitative reverse-transcriptase polymerase 
chain reaction should be performed every 3 months until a 
major molecular remission has been confirmed, and thereafter 
at least every 6 months. Currently, European Leukemia Net 
recommendations require obtaining a complete cytogenetic 
remission at 12 months and a major molecular remission at 
18 months.31 As time increases without achieving a   complete 
cytogenetic remission, the probability of obtaining this dimin-
ishes and the risk of progression increases.40   Physicians are 
encouraged to be vigilant in pursuit of therapeutic goals.
With the addition of second-generation TKIs to frontline 
therapy, the use of the terms “event-free survival” and 
“progression-free survival” to define particular agents is 
under some scrutiny due to a lack of standardization. 
  Differing definitions exist depending on the study and 
  institution. In the IRIS trial, event-free survival was defined 
as occurrence of any of the following: death from any cause; 
progression to advanced accelerated phase or blast phase 
CML, loss of complete hematologic response or major cyto-
genetic response, or an increasing white blood cell count 
(.20 × 109/L),5 whereas event-free survival at the MD 
Anderson Cancer Center is coded as event equals progression 
to   accelerated phase/blast phase in addition to loss of major 
Table 1 European LeukemiaNet (ELN) definitions of response31
Complete Hematologic Response (CHR)
wBC , 10 × 109/L
Platelets , 450 × 109/L
Basophils , 5%
No myelocytes, promyelocytes, myeloblasts in differential
Nonpalpable spleen
Cytogenetic Response (CR)
Complete (CCyR) – 0% Ph-positive metaphases
Partial (PCyR) – 1%–35% Ph-positive metaphases
Minor (mCgR) – 36%–65% Ph-positive metaphases
Minimal (minCgR) – 66%–95% Ph-positive metaphases
Molecular Response (MR)
Complete (CMR) – BCR-ABL transcript is nonquantifiable by RT-PCR**
Major (MMR) – Ratio of the BCR-ABL:ABL # 0.1% on international scale
Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights 
reserved. 
Note: **Must be confirmed in at least 2 sequential samples.
Abbreviations: wBC, white blood cell; BCR-ABL, breakpoint cluster region-abelson 
murine leukemia viral protooncogene.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
68
DeRemer et al
cytogenetic response, loss of complete hematologic response, 
patient off TKI for toxicity, and death from any cause on or 
off therapy.41 For nilotinib in the ENESTnd (Evaluating 
Nilotinib Efficacy and Safety in Clinical Trials-Newly 
  Diagnosed) study, progression was defined as advancing to 
accelerated phase/blast phase on TKI therapy, in addition 
to CML-related death on therapy.42 As more patients receive 
second-generation TKIs in frontline therapy, it is necessary 
to standardize these commonly used terms to make better 
long-term comparisons with imatinib.
Nilotinib in frontline CML 
treatment
The study by Rosti et al43 evaluated nilotinib 400 mg twice 
daily in chronic phase CML patients who were diagnosed 
up to 6 months before study entry. Patients could have 
received hydroxyurea or anagrelide prior to study enrollment. 
This multicenter single-arm study did not permit dose 
  escalation, but patients could receive dose modifications 
based upon hematologic and nonhematologic adverse events. 
Bone marrow aspirates were performed at months 3, 6, 
and 12 for cytogenetic analysis. Quantitative BCR–ABL 
transcript analysis was evaluated in peripheral blood samples 
collected at months 1, 2, 3, 6, 9, and 12. A major molecular 
remission was defined as a BCR–ABL:ABL ratio reduction 
of at least threefold. Achieving a major molecular remission 
has been associated with durable remission rates, and is a 
goal of current oral TKI-based CML therapy.1,36 A failure to 
obtain a major molecular remission within 18 months of 
treatment indicates a suboptimal response.44
The primary endpoint for this study was a complete 
cytogenetic remission at 1 year. Secondary endpoints 
included complete and partial cytogenetic responses at 
6 months, major molecular remission at 1 year, development 
of BCR–ABL mutations during treatment, and safety and 
tolerability of nilotinib 400 mg twice daily. Seventy-three 
patients were enrolled in this Phase II study. A complete 
hematologic response was reported in 100%, 98%, and 97% 
at months 3, 6, and 12, respectively, in all patients. Notable 
complete cytogenetic remission was also described, ie, 78%, 
96%, and 96% at months 3, 6, and 12. At the time of   publication, 
only one patient who had achieved a complete cytogenetic 
remission at 3 months relapsed to blast crisis with a T315I 
BCR–ABL mutation at 6 months.43 Updated information 
from this trial was presented at the 2009 American Society 
of Hematology meeting. Seventy-four percent of study 
  participants received a median daily nilotinib dose of 
600–800 mg. However, during the first year of the study, 
treatment was interrupted in 38 patients (52% overall, 86 inter-
ruptions) at least once. The median cumulative duration of 
nilotinib interruption was 19 (range 3–169) days per patient. 
Adverse events and tolerability of nilotinib will be discussed 
later in this review. With a median follow-up of 15 (range 
12–24) months, complete cytogenetic remission at 12 months 
was 96%, and major molecular remission was 85%.45
Investigators at MD Anderson Cancer Center also 
  evaluated nilotinib as frontline treatment in a single-arm 
Phase II study. Patients received nilotinib 400 mg twice daily, 
administered on an empty stomach. To be eligible for study 
enrollment, patients were required to have had a diagnosis 
of CML during the 6 months before the study, have had no 
treatment other than hydroxyurea or a 1-month maximum 
of imatinib 400 mg daily, be aged $18 years, have perfor-
mance status of 0–2, and normal organ function. The primary 
  objective of this study was to evaluate the major molecular 
remission rate at 12 months compared with historical 
  controls (from the IRIS study) who had received imatinib 
400–800 mg daily. Other endpoints evaluated were over-
all survival, event-free survival, and transformation-free 
survival.46
Sixty-one patients were evaluated in this analysis. Twelve 
patients (20%) had received a standard dose of imatinib for 
a median 22 (range 2–28) days prior to initiating nilotinib. 
At the time of publication, median follow-up was 17 (range 
1–43) months. Fifty-one patients had been enrolled on study 
for a minimum of 3 months, and thus were evaluable for 
molecular and cytogenetic response. The median time 
to major molecular remission was 3 months (range 3–18) 
months and was achieved by 39 (76%) of patients at this 
time point. At 12 months, 81% of patients had achieved a 
major molecular remission.46 These molecular responses 
favored nilotinib over imatinib based on historical controls. 
The standard dose of imatinib 400 mg daily produced a major 
molecular remission in 46% of patients at 12 months, whereas 
imatinib 800 mg daily led to a major molecular remission in 
54% of patients.47 Cytogenetic responses also favored 
patients who had received nilotinib therapy. Early and durable 
cytogenetic responses have been reported. The median 
time to achieve a complete cytogenetic remission was three 
(range 3–6) months; 90% and 96% of patients achieved a 
complete cytogenetic remission at months 3 and 6, respectively. 
In patients who received imatinib 400 mg daily, a complete 
cytogenetic remission was observed in 45% at 6 months.46 
High-dose imatinib (800 mg/daily) produced a complete Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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cytogenetic remission in 70% of patients at 12 months.47 
This increased rate and onset of cytogenetic response is 
controversial, but has been associated with less risk of disease 
progression. Given the durable complete cytogenetic remis-
sion rates, as expected, the estimated event-free survival at 
24 months was 90% and the transformation-free survival 
rate was 98%.46 These data continue to demonstrate the 
efficacy of nilotinib in newly diagnosed patients with chronic 
phase CML.
A lower nilotinib dose of 300 mg twice daily was evalu-
ated in untreated CML patients in the All-Ireland Cooperative 
Oncology Research Group 0802 open-label Phase II study. 
This group investigated the ability of lower dosing to pro-
duce an improved adverse event profile. The primary 
  endpoint of this study was complete cytogenetic remission 
at 6 months, and secondary endpoints included molecular 
response   determined at baseline and at monthly intervals. 
A new rapid turnaround polymerase chain reaction system, 
ie, “  GeneXpert”, was also evaluated. By intent to treat analysis, 
64% (16/25 patients) achieved a complete cytogenetic remis-
sion at 3 months and 95% (19/20 patients) at 6 months. 
At 6 months, 60% (12/20 patients) achieved a major 
molecular remission. Investigators did report that there was 
a trend to underestimate the BCR:ABL/ABL percentage 
which overestimates major molecular remission via the 
GeneXpert system.48 Only three patients (12%) have 
required an increased dose to 400 mg bid due to suboptimal 
results. Grade 3/4 hematologic toxicities were minimal, 
with only two patients (5%) developing Grade 3 thrombo-
cytopenia. This study continues to confirm nilotinib 300 mg 
bid is a safe and efficacious option for newly diagnosed 
CML patients.48
In the open-label, multicenter Phase III ENESTnd study, 
patients were eligible within six months of diagnosis of CML, 
and were excluded if they had received imatinib or any other 
treatment (except hydroxyurea or anagrelide) for more than 
2 weeks. In this study, patients were randomized in a 1:1:1 
ratio to receive imatinib 400 mg daily, nilotinib 300 mg twice 
daily, or nilotinib 400 mg twice daily.42 Randomization for 
ENESTnd was stratified according to the Sokal risk score.49 
Patients who had a suboptimal response, as defined by the 
European Leukemia Net,44 could escalate to imatinib 400 mg 
twice daily. However, patients were not allowed to cross 
over to other cohorts. The primary endpoint of this investiga-
tion was the rate of achievement of a major molecular remis-
sion at 12 months.42 As with other studies, this was defined 
as a reduction of at least three log copies of BCR–ABL 
transcripts as compared with baseline (established 
from the IRIS trial).2,37 In this study, all quantitative reverse-
  transcriptase polymerase chain reaction assays were per-
formed in one central laboratory (Molecular MD).   Secondary 
endpoints were the rate of complete cytogenetic remission 
at 12 months and durability of major molecular remission at 
24 months.42
A total of 846 patients were enrolled in ENESTnd. 
  Treatment arms were balanced according to age, gender, 
Sokal risk score,49 and median time of diagnosis prior to 
enrollment. At 12 months, major molecular remission rates 
were significantly better in patients who received nilotinib 
300 mg twice daily (44%) versus nilotinib 400 mg twice 
daily (43%) versus imatinib 400 mg daily (22%); P , 0.001 
for both comparisons.42
Recently, 18-month follow-up data from ENESTnd was 
presented at the 2010 American Society of Hematology 
meeting (see Table 2). A complete molecular response was 
defined by a BCR–ABL transcript level #0.0032% (inter-
national scale); 21% and 17% of patients on nilotinib 300 mg 
twice daily and nilotinib 400 mg twice daily, respectively, 
achieved this target, compared with only 6% of patients in 
the imatinib group. The secondary endpoint of complete 
cytogenetic remission rate at 18 months also favored the 
nilotinib groups, ie, 300 mg twice daily (85%, P , 0.001) 
versus nilotinib 400 mg twice daily (82%, P = 0.017) versus 
imatinib 400 mg daily (74%). Furthermore, the progression 
Table 2 Updated phase iii studies of second generation TKis in front-line therapy
n Study arm CCyR @ 18 months MMR @ 18 months
eNeSTnd50 study 282 Nilotinib 300 mg twice daily 85
P , 0.001
66
P , 0.001 281 Nilotinib 400 mg twice daily 82
P , 0.017
62
P , 0.001
283 imatinib 400 mg daily 74 40
n Study arm CCyR @ 18 months MMR @ 12 months
DASiSiON52 study 259 Dasatinib 100 mg daily 78
P = 0.0366
57
P , 0.002 260 imatinib 400 mg daily 70 41
Abbreviations: CCyR, complete cytogenetic response; MMR, major molecular response.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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of disease rate was significantly lower in the nilotinib groups, 
ie, 300 mg twice daily (0.7%, P = 0.006) and 400 mg 
twice daily (0.4%, P = 0.003) compared with imatinib (4.2%). 
At 18 months, all three arms produced similar overall survival 
rates of 98.5% (P = 0.28), 99.3% (P = 0.03), and 96.9%, 
respectively.50 As follow-up of this study continues, it will be 
interesting to evaluate the discontinuation rates in the nilotinib 
arms. To date, discontinuation due to adverse events is 7% for 
nilotinib 300 mg twice daily versus 12% for   nilotinib 400 mg 
twice daily. These promising results suggest that nilotinib 
should continue to be a new frontline treatment option.
Other second-generation TKIs  
in frontline therapy
Although not strictly comparable given the differences in 
study inclusion criteria, the results of ENESTnd are com-
monly discussed in relation to DASISION (Dasatinib versus 
Imatinib Study in Treatment Naïve CML Patients) because 
both studies evaluated a second-generation TKI against 
imatinib as frontline therapy for CML. As with nilotinib, 
dasatinib induced a significantly faster and higher complete 
cytogenetic remission (dasatinib 77%, imatinib 66%; 
P = 0.007) at 12-month follow-up. The rates of major molecu-
lar remission also favored dasatinib (83% versus 72%; 
P = 0.001).51 A recent 18-month update of this study contin-
ues to demonstrate the superiority of dasatinib with regard 
to complete cytogenetic remission (78% versus 70%; 
P = 0.0366). The major molecular remission rate at any time 
during the study also favored dasatinib (57% versus 41%; 
P = 0.0002).52 Rates of progression-free survival at this 
interim analysis were 94.9% for dasatinib and 93.7% for 
imatinib. Fewer patients progressed to accelerated phase or 
blast phase CML while receiving dasatinib (n = 6 [2.3%] 
versus n = 9 [3.5%]) compared with imatinib.
Interim results of an ongoing randomized, open-label, 
Phase III study of bosutinib (SKI-606) versus imatinib in 
newly diagnosed CML patients known as BELA (Bosutinib 
Efficacy and safety in chronic myeloid LeukemiA) was 
presented at the 2010 American Society of Hematology 
meeting. Patients were randomized to bosutinib 500 mg daily 
or imatinib 400 mg daily. The study did not meet its primary 
endpoint of superior complete cytogenetic remission at 
12 months (bosutinib 70%, imatinib 68%; P = 0.601) in the 
intent to treat population. However, patients did achieve a 
faster complete cytogenetic remission if receiving bosutinib 
(13 weeks versus 25 weeks; P , 0.001). As expected, the 
cytogenetic responses for second-generation TKIs were 
higher in a frontline setting when compared with the previous 
Phase II studies performed in imatinib-resistant or imatinib-
intolerant patients (see Table 3). The BELA study did meet 
its secondary endpoint. A higher proportion of patients 
treated with bosutinib achieved higher major molecular 
remission rates (39% versus 26%; P = 0.006). Furthermore, 
fewer patients (n = 4, 1.6%) who received bosutinib 
  progressed to advanced CML than those on imatinib 
(n = 10, 3.2%). Based upon these results, efforts to seek 
approval for bosutinib by the FDA and European Medicine 
Agency in newly diagnosed CML patients are underway.53
Resistance
The current National Comprehensive Cancer Network guide-
lines for CML recommend that a complete hematologic 
response should be achieved at 3 months, a complete cyto-
genetic remission or partial cytogenetic response at 6 months, 
and a complete cytogenetic remission at 12 and 18 months 
for frontline therapy.1 This recommendation is based upon 
imatinib data, and the National Comprehensive Cancer Net-
work panel recommends the same evaluation points if dasa-
tinib or nilotinib are used as initial therapy. If a patient starts 
nilotinib as frontline therapy and does not achieve an adequate 
clinical response, several issues should be considered. 
  Foremost, patient adherence should be addressed. Poor patient 
Table 3 Phase ii studies of second generation TKis in imatinib resistant or intolerant CML-CP and -AP patients
Author n Dose Stage of disease CHR (%) MCyR (%) CCyR (%)
Nilotinib
Kantarjian8 321 400 mg BiD -CP 77 57 41
leCoutre9 119 400 mg BiD -AP 26 29 16
Dasatinib
Hochhaus10,13 387 70 mg BiD -CP 91 59 49
Guilhot11 107 70 mg BiD -AP 39 33 24
Bosutinib
Cortes12 283 500 mg Qday -CP 79 40 29
Gambacorti-Passerini14 44 500 mg Qday -AP 64 69 14
Abbreviations:  CML-CP,  chronic  phase;  CML-AP,  accelerated  phase;  CHR,  complete  hematologic  response;  MCyR,  major  cytogenetic  response;  CCyR,  complete 
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adherence has been associated with suboptimal outcomes in 
patients receiving imatinib.54–56 If BCR–ABL transcripts 
continue to increase despite patient adherence, other factors, 
such as the development of point mutations, increased expres-
sion of BCR–ABL, drug interactions with CYP3A4 inducers, 
decreased bioavailability, and P-glycoprotein expression 
should be considered.57,58 Currently there are no available 
guidelines which suggest specific increases of BCR–ABL 
transcripts that warrant a change in current therapy. It is 
important to note that the presence of a BCR–ABL mutant 
does not necessarily lead to resistance. Although a 2–3-fold 
increase in BCR–ABL has been suggested to be indica-
tive of kinase mutations,59 mutational analysis screening 
should be performed if inadequate response to nilotinib is 
reported.
Over 50 point mutations with varying degrees of resis-
tance have been identified with imatinib.58,60 Recent clinical 
data have suggested that approximately 50%–90% of patients 
with imatinib resistance will have a BCR–ABL kinase 
mutation.60,61 In recent years, second-generation TKIs 
have provided a therapeutic option for those harboring spe-
cific BCR–ABL mutations which lead to imatinib resistance. 
In this setting, the specific mutation contributes to the sequen-
tial therapeutic choice of which TKI to select. As these agents 
transition themselves to become potential firstline treatment 
options, it will become important to continue to assess BCR–
ABL kinase mutational status during therapy. ABL kinase 
mutations are generally described by location and are num-
bered by specific amino acid residues.62 The ABL kinase 
domain consists of the P-loop, activation loop, and the cata-
lytic domain.63 Mutations can occur via direct inhibition by 
altering an amino acid, which impairs drug binding without 
affecting adenosine triphosphate binding. An example of this 
is the substitution of phenylalanine for leucine mutation at 
codon 317. Mutations can also occur in amino acid residues 
which are involved in the conformational change of BCR–ABL. 
For example, a tyrosine to histidine mutation at 253 break 
hydrogen bond interactions specific for distortion of the 
P-loop.61 X-ray crystallographic analysis of multiple mutant 
ABL alleles in imatinib-resistant patients was essential for 
the screening and development of second-generation TKIs. 
In the case of nilotinib, a N-methylpiperazine ring that par-
ticipated in hydrogen bonding with Ile360 and His361 in the 
imatinib molecule was replaced. Whereas imatinib requires 
six hydrogen bonds to stabilize binding, nilotinib requires 
only four. This alteration increased the affinity for the   inactive 
conformation of BCR–ABL by 20–30-fold.20,64 Despite this 
increased potency, resistance can still occur.
Mutations that are highly resistant (IC50 . 150 nM) to 
nilotinib include Y253H, E255K/V , F359C/V , and T315I.65–68 
In a multivariate analysis, chronic phase CML patients with 
E255K/V, Y253H, or F359C/V had a significantly shorter 
progression-free survival (hazards ratio 6.097, P # 0.0001) 
with nilotinib following imatinib failure.69 Hughes et al also 
reported that mutations E255K/V, Y253H, and F359C/V 
were associated with less in vitro sensitivity and lower 
clinical response rates. Furthermore, none of these patients 
were able to obtain a complete cytogenetic remission at 
12 months of therapy, six (19%) achieved a molecular and 
cytogenetic remission, and 10 (32%) achieved a complete 
hematologic response.66 Patients who harbor the T315I 
mutation are not responsive to imatinib, nilotinib, or dasa-
tinib.65 This mutation usually affects patients in advanced 
stages of accelerated phase/blast crisis CML as well as acute 
lymphoblastic   leukemia. These patients may respond to 
investigational agents, such as AP24534 or omacetaxine, 
and should pursue allogeneic stem cell transplantation.70–72 
There has been some concern about selecting for T315I 
with the increased use of second-generation TKIs. To date, 
this has not been   demonstrated. Other mutations that have 
varying degrees of resistance to nilotinib include G250E, 
F359V, L248V, Q252H, Y253F, E279K, F317L, L384M, 
H396P, and H396R.65 Interestingly, nilotinib failure can be 
seen in P-loop mutations, such as the previously mentioned 
Y253H and E255K/V .65,73,74 However, other P-loop mutants 
(L248V , G250E, and Q252H) have demonstrated in vitro 
sensitivity to nilotinib. Jabbour et al75 reported no differ-
ences in overall survival with the presence of P-loop muta-
tions in patients who received second-generation TKIs 
following imatinib. The G250E mutation classification is 
controversial. Some classify this mutation as resistant to 
imatinib, dasatinib, nilotinib, and bosutinib,65 whereas 
O’Hare et al76 report this mutation to be sensitive (IC50 
48 nM for nilotinib and 1.8 nM for dasatinib) to second-
generation TKIs. The mutation F317L located in the adenos-
ine triphosphate binding region is associated with resistance 
to dasatinib, and these patients may respond positively to 
nilotinib.65,77,78
Data on resistance with second-generation TKIs used 
frontline will continue to emerge as the relevant studies 
mature. There is a concern that earlier exposure to nilotinib 
could result in new and more resistant mutations. Early data 
presented at the 2010 American Society of Hematology 
meeting appear to be promising. In ENESTnd, with a median 
follow-up of 18 months, mutational testing was performed 
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bid, and imatinib arms, respectively. Patients who developed 
a BCR–ABL mutation were as follows: nilotinib 300 mg 
twice daily (8 [3%]), nilotinib 400 mg twice daily (5 [2%]), 
and imatinib (16 [6%]). The eight BCR–ABL mutations 
in the nilotinib 300 mg twice daily group were identified in 
six patients. These included Y253H, Y253H/F359V , E255K/
T315I, T315I, F359V, and E2459K. Y253H, E255K, and 
F359V were deemed less sensitive, but not inherently 
  resistant, as was the T315I identified in three patients receiv-
ing nilotinib. Six of 16 imatinib-treated patients (38%) with 
BCR–ABL mutations progressed to accelerated phase/blast 
crisis CML, as compared with 1/13 (8%) of nilotinib-treated 
patients.79 Investigators at MD Anderson Cancer Center also 
recently presented their institutional history with nilotinib 
(n = 90) and dasatinib (n = 82) used in frontline CML therapy 
or for accelerated phase CML patients who had not been 
previously treated. In this retrospective analysis, 13 (16%) 
discontinued nilotinib therapy due to adverse events, 
  progression, or other reasons. Three patients (two of whom 
were treated during an accelerated phase) receiving nilotinib 
progressed to blast crisis. Fourteen patients had BCR–ABL 
mutation analysis performed. Only two mutants (F359C and 
Y253H) were reported.80 Cortes et al46 reported that one 
patient who had never achieved a major molecular remission 
developed a E255K mutation after 8 months on frontline 
nilotinib therapy. Two further patients in this study discon-
tinued nilotinib due to intolerance and later progressed to 
blast crisis, one of whom developed a F359C mutation. 
Although BCR–ABL mutations are still being identified 
despite nilotinib use in frontline therapy, accounting for the 
number of patients receiving this therapy and comparing 
imatinib data, it does not appear that the use of nilotinib is 
associated with an increased risk of inducing BCR–ABL 
mutations.
Tolerability
Nilotinib is well tolerated with a favorable risk-benefit 
  profile. Most adverse events are categorized as Grade 1/2 
toxicities and are manageable. These toxicities include rash, 
pruritus, and headache. The most common Grade 3/4 non-
hematologic events include biochemical abnormalities, such 
as elevations in bilirubin, amylase, and lipase. These adverse 
events are a common cause of dose interruption or discon-
tinuation.81 Biochemical abnormalities, such as hypergly-
cemia and hypophosphatemia, are associated with nilotinib. 
As with other oral TKIs used to treat CML, myelosuppres-
sion may be severe and require dose reduction. Second-
generation TKIs have been associated with higher Grade 
3/4 neutropenia and thrombocytopenia rates, but these 
agents were predominantly evaluated in imatinib-resistant 
patients who would be more likely to have impaired 
hematopoiesis.82 Nilotinib is associated with less fluid 
retention when compared with imatinib and dasatinib.83 
Furthermore, nilotinib is less likely to be associated with 
pleural or pericardial effusions (,1% of Grade 3/4 events) 
when compared with dasatinib. Although uncommon, car-
diac toxicities, such as congestive heart failure, left ven-
tricular dysfunction, and QT prolongation, have also been 
observed.81
Nonhematologic toxicity
The most frequently reported all-grade nonhematologic 
adverse events associated with nilotinib 400 mg twice 
daily in imatinib-resistant or imatinib-intolerant patients 
include rash (33%), headache (31%), pruritus (29%), and 
fatigue (28%).81 Serum biochemical abnormalities are the 
most clinically relevant adverse events. Le Coutre et al9 
reported Grade 3/4 lipase elevations in 18% of 119 acceler-
ated phase CML patients in a Phase II study. In this study, 
Grade 3/4 amylase elevations occurred in 2% of patients, 
one of whom discontinued therapy due to pancreatitis. 
Hepatic transaminase elevations (,2% Grade 3/4) have 
also been reported. Hyperbilirubinemia has also been 
observed, but is usually self-limiting despite continued 
treatment.8 It is recommended that patients with $Grade 3 
elevations in amylase, bilirubin, or transaminases should 
temporarily discontinue therapy and resume treatment at 
400 mg daily.81
Cardiac toxicity, namely QT prolongation, has been 
reported with nilotinib. Kantarjian et al8 in a Phase I 
study analyzed more than 2200 electrocardiograms from 
119 patients. Mean increases of Fredericia’s corrected QT 
interval (QTc) were 5–15 msec in patients who received 
nilotinib. Le Coutre et al9 observed QTc increases .60 msec 
in 4% of patients, but no episodes of torsades de pointes were 
reported. In contrast, mean changes of QTc on dasatinib were 
3–6 msec, whereas imatinib has not been reported to prolong 
the QTc interval.82 To date, five sudden deaths have been 
reported in clinical studies (n = 867; 0.6%). Patients with 
hypokalemia or hypophosphatemia should have electro-
lyte abnormalities corrected prior to initiation of nilotinib. 
  Furthermore, concurrent use of CPY3A4 inhibitors should 
be avoided to prevent possible increases in the QT interval. 
The manufacturer recommends that electrocardiograms be 
performed at baseline, a week following initiation of therapy, 
and periodically thereafter.81Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Although imatinib and nilotinib are structurally similar, 
their well known toxicities such as fluid retention, edema, 
and weight gain, are less common with nilotinib.81,84 
In Phase II clinical trials evaluating nilotinib, all-grade pleu-
ral effusions were reported in ,1% of patients.8,9 In contrast, 
pleural effusions were reported in 27%–31% of patients in 
clinical studies evaluating dasatinib 140 mg daily.10,85 
  However, recent Phase III trials evaluating dasatinib 100 mg 
daily have reported a lower all-grade incidence of pleural 
effusion (7%–10%).51,86 It has been proposed that nilotinib 
is associated with less fluid retention because it has a weaker 
affinity for platelet-derived growth factor beta than does 
imatinib and dasatinib (IC50 for platelet-derived growth factor 
53 nM for nilotinib, 39 nM for imatinib, and 28 nM for 
dasatinib).20,83,87 Platelet-derived growth factor-beta receptors 
have been shown to regulate interstitial fluid pressure and 
thus control transport from the vasculature into the extracel-
lular space.88 Thus, possible “off-target” inhibition of these 
receptors may explain this higher incidence of peripheral and 
pulmonary edema. However, an immune-mediated etiology 
has also been proposed due to lymphocyte-predominant 
exudative effusions secondary to dasatinib use.83,89 In a ret-
rospective study, 62 CML patients treated with dasatinib 
were evaluated to identify predictive factors. In a multivariate 
analysis, independent predictors of pleural effusions were 
skin rash (relative risk [RR] 5.3, 95% confidence interval 
[CI]: 1.9–14.6; P , 0.0001), previous history of autoimmune 
disease (RR 4.4, 95% CI: 1.3–14; P , 0.015), and hyper-
cholesterolemia (RR 3.5, 95% CI: 1.8–14.6, P = 0.037).90 
Other factors which have been implicated include previous 
lung problems (infection/smoking), hypertension, advanced 
disease, and those maintained on dasatinib 70 mg bid.91,92 
The development of pleural effusions appears to be multi-
factorial, and offers a potential selective advantage for 
nilotinib as frontline therapy in certain patient populations.
Hematologic toxicity
Neutropenia and thrombocytopenia were the most commonly 
reported hematologic toxicities in Phase II trials evaluating 
nilotinib in imatinib-resistant or imatinib-intolerant patients. 
In patients with chronic phase CML (n = 318), nilotinib 
400 mg twice daily was associated with $Grade 3 neutropenia 
(28%) and thrombocytopenia (28%).93 Increased $Grade 3 
rates of myelosuppression (neutropenia 37%, thrombocy-
topenia 37%) have been reported in patients (n = 119) with 
advanced accelerated phase CML.9 Dose reductions are not 
warranted for Grade 1/2 toxicities. In patients receiving 
nilotinib 400 mg twice daily for resistant or intolerant 
chronic or accelerated phase CML, an absolute neutrophil 
count ,1 × 109/L or platelet count ,50 × 109/L does requires 
transient cessation and possible dose reduction.81 In a retro-
spective analysis performed at MD Anderson Cancer Center, 
dose reductions/interruptions of both nilotinib and dasat-
inib were analyzed in all-phase CML patients. A total of 
280 patients were analyzed, and nilotinib was used in 
129 (46%) patients. The most common reason for dose reduc-
tion was thrombocytopenia (31%), elevated bilirubin (16%), 
and neutropenia (14%). Interestingly, in this analysis, dose 
reductions/interruptions had no impact on response rates for 
either agent. These data led the authors to postulate that lower 
doses of either TKI could be used in CML.94 Data from the 
ENESTnd study confirmed that a lower dose of nilotinib 
(600 mg daily) was as efficacious, may have less toxicity, 
and could be more cost-effective.42
Specific toxicity in frontline  
therapy
Rosti et al43 evaluated nilotinib 400 mg twice daily in previ-
ously untreated patients with chronic phase CML. Similar 
rates of all-grade nonhematologic toxicities were observed, 
including skin rash (42%), bone/muscle pain (41%),   headache 
(30%), fatigue (22%), and pruritus (21%). Grade 3 hyper-
bilirubinemia was noted in 16% of patients. Kantarjian et al8 
reported that 9% of previously treated patients experienced 
this Grade 3/4 toxicity. Electrocardiographic monitoring was 
performed, and transient abnormalities were observed 
in 16 patients, but none had a QT interval .500 msec. 
  Hematological events were exceedingly rare, with only 4% 
and 2% experiencing Grade 3 or 4 neutropenia and throm-
bocytopenia, respectively. Temporary dose interruptions 
were needed in 52% of patients, for an average duration of 
19 days. Cortes et al46 reported higher rates of myelosuppres-
sion, but this was comparable with previous imatinib data in 
untreated patients. Nilotinib was associated with Grade 3/4 
anemia (5%), neutropenia (12%), and thrombocytope-
nia (11%). Grade 3/4 toxicities observed for imatinib 400 mg 
daily in the IRIS trial comprised anemia (3%), neutropenia 
(14%), and thrombocytopenia (8%).2 In ENESTnd, the nilo-
tinib 300 mg twice daily arm had Grade 3/4 toxicities of 
anemia (5%), neutropenia (12%), and thrombocytopenia 
(10%), respectively, compared with the imatinib 400 mg 
daily arm, in which rates of these toxicities were 5%, 20%, 
and 9%, respectively. Furthermore, the nilotinib 300 mg 
twice daily arm had the lowest discontinuation rate (5%) due 
to adverse events42 (see Table 4 for comparison of adverse 
events on nilotinib and dasatinib in the Phase III studies). Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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These observations suggest that nilotinib is a safe frontline 
treatment option for patients with chronic phase CML.
Quality of life
The advent of the first-generation and second-generation 
TKIs in the treatment of CML has dramatically improved 
the quality of life of patients afflicted with this disease when 
compared with previous treatments, such as interferon and 
oral busulfan. Participants in the IRIS trial completed the 
Functional Assessment of Cancer Therapy-Biologic 
Response Modifiers (FACT-BRM) which is a validated 
40-question instrument.95 Patients completed the FACT-BRM 
at baseline, and at months 1, 2, 3, 4, 5, 6, 9, and 12 following 
initiation of treatment with either imatinib or cytarabine-
interferon. Across all baseline data collection points, the ima-
tinib arm (n = 530) performed significantly (P , 0.001) better 
in terms of the Trial Outcome Index score than the cytarabine-
interferon group (n = 519).96 In patients who were intolerant 
to imatinib therapy, second-generation TKIs have provided 
clinical benefit, with a generally improved toxicity profile. 
Formal comparative quality of life and economic analysis 
are needed for these agents. An ongoing study (NCT00980018) 
is assessing quality of life from baseline to the end of cycles 
1, 3, 6, 9, and 12 in patients switching from imatinib to 
nilotinib. This investigation will assess the change in the MD 
Anderson Symptom Inventory Module (MDASI-CML) 
symptom-burden tool which is currently under evaluation.97 
The MDASI-CML rates the severity of symptoms (13 items) 
and interference with activities of daily living (six items).98 
Ongoing research into patient-reported symptoms and sup-
portive care methods continues. This will be crucial for the 
future of treating CML. Patients may be required to tolerate 
chronic toxicities from indefinite TKI therapy.
Conclusion
The development of BCR–ABL kinase inhibitors which was 
initiated in the mid-1990s has been tremendously successful.99 
The establishment of imatinib in 2001 as frontline therapy 
transformed the treatment of CML dramatically. Ten years 
later, new questions have emerged. Foremost, should front-
line treatment of CML change to a second-generation TKI? 
The answer to this question is complex and continues to be 
examined. As we continue to follow original IRIS study 
participants, impressive 85% overall survival and 81% 
event-free survival rates have been demonstrated with ima-
tinib at 8 years.5 In addition, the estimated annual risk of 
treatment failure was 3.3%, 7.5%, 4.8%, 1.5%, and 0.9% 
in the first 5 years of therapy.3 Some would suggest continu-
ing imatinib as frontline therapy due to its notable efficacy, 
more experience with its use, and the fact that, if a patient 
become resistant or intolerant, several second-generation 
TKIs are available. However, some have debated whether 
imatinib 400 mg daily should be the recommended dose 
for newly diagnosed CML patients. Trials evaluating higher 
doses of imatinib (600 or 800 mg daily) have produced a 
deeper molecular response. Kantarjian et al100 evaluated 
imatinib 800 mg daily in newly diagnosed chronic phase 
patients (n = 114). High-dose imatinib produced improved 
complete cytogenetic remission (P = 0.0005), major molecu-
lar remission (P = 0.00001), and complete molecular 
response (P = 0.001) compared with standard imatinib. 
Achieving a cytogenetic and molecular response, and at 
what time point, is a significant concern. For example, none 
of the patients who achieved a complete cytogenetic remis-
sion at 12 months with imatinib progressed to the accelerated 
phase or blast crisis.5 This suggests that if a more potent 
BCR–ABL inhibitor, such as nilotinib, was used in frontline 
Table 4 Selected adverse event profile of BCR-ABL TK inhibitors in front-line CML therapy
Imatinib 400 mg daily42  
(n = 280)
Dasatinib 100 mg  
daily51 (n = 258)
Nilotinib 300 mg  
BID42 (n = 279)
Nilotinib 400 mg  
BID42 (n = 277)
All Grades  
%
Grades 3–4  
%
All Grades  
%
Grades 3–4  
%
All Grades  
%
Grades 3–4  
%
All Grades  
%
Grades 3–4   
%
Neutropenia 68 20 65 21 43 12 38 10
Thrombocytopenia 56 19 70 19 48 10 49 12
Anemia 47 5 90 10 38 3 38 3
Nausea 31 0 8 0 11 ,1 19 1
vomiting 14 0 5 0 5 0 9 1
Rash 11 1 11 0 31 ,1 36 3
Arthalgia/Myalgia -/10 -/0 -/6 -/0 -/10 ,1 -/10 -/0
Peripheral edema 14 0 NR NR 5 0 5 0
Pleural effusion NR NR 10 0 NR NR NR NR
Abbreviation: NR, not reported.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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therapy, potentially fewer patients would progress to 
advanced disease.
It could be assumed that the ability of nilotinib to produce 
deeper molecular responses would be associated with 
improved progression-free survival and overall survival. 
However, a lack of correlation between achieving a molecular 
response and improving overall survival has been reported 
in patients receiving imatinib. These same investigators did 
show that patients who achieved a complete cytogenetic 
remission and major molecular remission (continuously for 
12 months) had improved progression-free survival but not 
overall survival.101 DeLavallade et al102 published similar 
results, whereby newly diagnosed patients who obtained a 
complete cytogenetic remission by 12 months had better 
progression-free survival and overall survival, but achieving 
a major molecular remission confirmed no advantage. Given 
the differences in major molecular remission (see Table 2) 
between nilotinib and imatinib in updated ENESTnd data, 
it will be interesting to evaluate overall survival in those 
patients which achieved a major molecular remission. 
  Currently, the estimated overall survival in the intent to treat 
population for nilotinib 300 mg twice daily is 98.5% and for 
imatinib is 96.9%. Given the lack of significant overall sur-
vival benefit at the approved 300 mg twice daily dose, factors 
such as fewer CML-related deaths, reduced progression 
to accelerated phase/blast crisis (particularly including 
clonal evolution), and lower incidence of BCR–ABL muta-
tions with nilotinib, all merit the use of nilotinib in a frontline 
setting.50,79
With the emergence of second-generation TKIs, inves-
tigations of combination therapy and a very active drug 
development pipeline that includes a pan-BCR–ABL inhibi-
tor (ponatinib),103 omacetaxine,71 Aurora-kinase inhibitors,104 
farnesyltransferase inhibitors,105 and histone deacetylase 
inhibitors,106,107 hope for a potential “cure” continues. Long-
term outcomes for second-generation TKIs used in frontline 
treatment will continue to emerge. We would encourage 
patients who are experiencing optimal responses, as defined 
by practice recommendations, to continue imatinib therapy. 
However, if patients experience suboptimal response or 
intolerance to imatinib, a switch to a second-generation TKI 
is warranted. The decision as to which particular agent should 
be individualized and take into consideration patient-specific 
information. Patients with a history of hypertension, smok-
ing, cardiac problems, chronic obstructive pulmonary dis-
ease, and advanced disease (more than accelerated phase) 
would be better candidates for nilotinib, to avoid the possible 
development of pleural effusions. Monitoring is warranted 
in nilotinib or dasatinib patients with a previous history of 
congestive heart failure or left ventricular dysfunction because 
QTc elongation has been noted with both agents. For diabetes 
patients, hyperglycemia needs to be carefully monitored 
because it could be exacerbated with the initiation of nilotinib. 
In conclusion, nilotinib 300 mg twice daily is a well tolerated 
and highly effective in newly diagnosed CML patients. 
  Nilotinib represents a new standard of care for CML patients.
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